Status:

COMPLETED

Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Lead Sponsor:

Tricida, Inc.

Conditions:

Metabolic Acidosis

Eligibility:

All Genders

18-85 years

Phase:

PHASE3

Brief Summary

This is a multicenter, double-blind, placebo-controlled, parallel-design study. The study will enroll approximately 210 adult male and female subjects with stage 3 or 4 chronic kidney disease and meta...

Eligibility Criteria

Inclusion

  • Key
  • Blood bicarbonate level of 12 to 20 mEq/L.
  • Estimated glomerular filtration rate (eGFR) of 20 to 40 mL/min/1.73m2.
  • Stable kidney function defined as \<=20% variability in eGFR during screening period.
  • Key

Exclusion

  • Any level of low blood bicarbonate during the screening period that in the opinion of the Investigator, requires emergency intervention or evaluation for an acute acidotic process.
  • Anuria, dialysis, acute kidney injury, or history of acute kidney insufficiency within 3 months prior to screening.
  • Heart failure with maximum New York Heart Association (NYHA) Class IV symptoms or that required hospitalization during the preceding 6 months.
  • Heart or kidney transplant.
  • Chronic obstructive pulmonary disease (COPD) that is treated with chronic oral steroids, that requires the subject to be on oxygen, or that required hospitalization within the previous 6 months.
  • Change in doses to alkali therapy in the 4 weeks prior to screening.
  • History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing disorders, inflammatory bowel disease, major gastrointestinal surgery, frequent diarrhea or active gastric/duodenal ulcers.
  • Serum calcium \<= 8.0 mg/dL at screening.
  • Planned initiation of renal replacement therapy within 12 weeks following randomization.
  • Use of polymeric binder drugs within 14 days prior to screening.

Key Trial Info

Start Date :

September 26 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 15 2018

Estimated Enrollment :

217 Patients enrolled

Trial Details

Trial ID

NCT03317444

Start Date

September 26 2017

End Date

May 15 2018

Last Update

April 26 2021

Active Locations (44)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (44 locations)

1

Investigative Site 55

Phoenix, Arizona, United States, 85032

2

Investigative Site 56

Chula Vista, California, United States, 91910

3

Investigative Site 91

Los Angeles, California, United States, 90022

4

Investigative Site 59

Hialeah, Florida, United States, 33015